Showing 4821-4830 of 5957 results for "".
- Judy F. Gordon, DVM, Founder of ClinReg Consulting Services, Retireshttps://modernod.com/news/judy-f-gordon-dvm-founder-of-clinreg-consulting-services-retires/2479004/Medical device and pharmaceutical consulting company ClinReg Consulting Services announced the retirement of its founder and president, Judy F. Gordon, DVM. Dr. Gordon has worked in the clinical and regulatory industry for more than 35 years, beginning with her career in the pharmaceutical
- AdHawk Microsystems Launches AdHawk MindLink Eye Tracking Researchhttps://modernod.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/AdHawk Microsystems announced the launch of AdHawk MindLink wearable eye tracking system. AdHawk MindLink produces accurate eye movement data to provide deep insights into human behavior, ocular, and neurological health. Delivered in the form of lightweight and comfortable glasses, the AdHawk sys
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Rochehttps://modernod.com/news/semathera-enters-into-a-research-collaboration-and-exclusive-license-agreement-with-roche/2478997/SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche to advance SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. Terms of the deal were not disclosed. “We are very
- Nidek Launches RT-6100 CB for Windows to Enhance Refraction Workflowhttps://modernod.com/news/nidek-launches-rt-6100-cb-for-windows-to-enhance-refraction-workflow/2478994/Nidek has announced the launch of RT-6100 CB for Windows, an optional control software for the RT-6100 Intelligent Refractor and the TS-610 Tabletop Refraction System. As the environment is shifting and the dem
- AstraZeneca’s COVID-19 Vaccine Shows 79% Efficacy in Pivotal US Studyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-shows-79-efficacy-in-pivotal-us-study/2478995/AstraZeneca on Monday announced that its vaccine AZD1222 demonstrated efficacy of 79% at preventing symptomatic COVID-19 in a late-stage study conducted in the US. Results also showed that the vaccine had 100% efficacy at preventing severe disease and hospitalization, with comparable effectivenes
- SIFI Receives Marketing Authorization for Ophthalmic Products in in Turkeyhttps://modernod.com/news/sifi-recevies-marketing-authorizations-for-ophthalmic-products-in-in-turkey/2478996/SIFI, has announced that the Turkish Medicines and Medical Devices Agency (TMMDA) has approved the transfer of marketing authorizations from its former local distributor to its wholly owned subsidiary SIFI İlaç A.S. The approvals cover different formulations of ophthalmic drugs Netira, Netildex,
- Senate Narrowly Confirms Becerra as HHS Secretaryhttps://modernod.com/news/senate-narrowly-confirms-becerra-as-hhs-secretary/2478991/The Senate has narrowly confirmed California Attorney General Xavier Becerra as secretary of the Department of Health and Human Services, according to a FierceHealthcare
- EMA’s Blood Clot Review Exonerates AstraZeneca COVID-19 Vaccine, But Monitoring Continueshttps://modernod.com/news/emas-blood-clot-review-exonerates-astrazeneca-covid-19-vaccine-but-monitoring-continues/2478990/The European Medicines Agency (EMA) on Thursday said a review by its Pharmacovigilance Risk Assessment Committee (PRAC) has determined that AstraZeneca’s COVID-19 vaccine AZD1222 is safe and effective at preventing COVID-19, and that its benefits are “far greater” than any poten
- BJO Publishes New Data on Clearside Biomedical’s Investigational Treatment Xiperehttps://modernod.com/news/bjo-publishes-new-data-on-clearside-biomedicals-investigational-treatment-xipere/2478989/New data has been published in The British Journal of Ophthalmology related to the clinical development program of Clearside Biomedical’s Xipere, an investigational treatment with a proposed indication of macular edema associated with noninfectious uveitis.